Response to: Concern regarding classification of germlineTP53 variants as likely pathogenic

Affiliations

• ¹ Division of Cancer Epidemiology and Genetics, Department of Health and Human Services, Clinical Genetics Branch, National Cancer Institute, National Institutes of Health, Bethesda, Maryland.
• ² Division of Research, National Cancer Institute, Mexico City, Mexico.
• ³ Department of Prevention and Therapy of Chronic Diseases, Team Tumor Molecular Pathology and Biomarkers, Institute for Advanced Biosciences, Inserm U 1209, UMR 5309 Université Grenoble Alpes, Site Santé, Allée des Alpes, 38700, La Tronche, France.
• ⁴ Department of Oncogenetics, International Research Center, A.C. Camargo Cancer Center, São Paulo, Brazil.
• ⁵ Head and Neck Surgery and Otorhinolaryngology Department, A.C. Camargo Cancer Center, São Paulo, Brazil.
• ⁶ Oncogenetics Unit, Oncology Center, Sírio-Libanês Hospital, São Paulo, Brazil.